Short- and medium-term mechanistic trials in T2DM show that SGLT-2 inhibitors produce modest reductions in office-measured and 24-h ambulatory BP [66, 71], central systolic BP and central pulse pressure [40]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.